NSPR
InspireMDยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NSPR fundamentals
InspireMD (NSPR) released its earnings on Nov 4, 2025: revenue was 2.52M (YoY +39.23%), beat estimates; EPS was -0.17 (YoY -6.25%), beat estimates.
Revenue / YoY
2.52M
+39.23%
EPS / YoY
-0.17
-6.25%
Report date
Nov 4, 2025
NSPR Earnings Call Summary for Q3,2025
- Revenue Surge: Q3 2025 revenue up 39% to $2.5M, driven by U.S. CGuard Prime launch and global expansion.
- Clinical Impact: Over 100 U.S. cases, 70k+ global stents sold, with tandem lesion study 50% enrolled.
- Financial Strength: 34.2% gross margin, $63.4M cash from financing, positioning for Q4 growth to $2.5-3.0M.
- Strategic Moves: New CMO, deliberate U.S. onboarding (12 reps, 12+ accounts), and premium pricing for broad adoption.
EPS
Revenue
Revenue & Expenses
NSPR has released its 2025 Q3 earnings report, with revenue of 2.52M, reflecting a YoY change of 39.39%, and net profit of -12.71M, showing a YoY change of -61.06%. The Sankey diagram below clearly presents NSPR's revenue sources and cost distribution.
Key Indicators
InspireMD (NSPR) key financial stats and ratios, covering profitability, financial health, and leverage.
InspireMD (NSPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
InspireMD (NSPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
InspireMD (NSPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does InspireMD (NSPR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track InspireMD (NSPR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
